Our understanding of the clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) is in its infancy when compared to better studied central nervous system demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). The gene discussed is MOG; the disease is neuromyelitis optica.